Investors

Print

We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

We have used our unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional drug treatments. Our lead therapeutic candidate is our ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This treatment is currently in clinical development. We are also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side effect of diabetes, and blindness-causing diseases of the retina.

We have also developed a range of stem cell lines for non-therapeutic applications – our ReNcell® products for use in academic and commercial research.  Our ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.

Our principal strategy is to gain clinical validation for our cell therapy programmes via well-designed clinical trials in well-regulated territories.  Ultimately, we expect to realise value for our technologies and therapeutic programmes via out-license to commercial development partners at the appropriate points in their development.  In order to achieve these objectives, we work closely with a number of key academic and industrial partners while continuing to maintain tight control over our financial resources.

Our shares are traded on the London AIM market under the symbol RENE.L.